Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus.

Emmanouil Peros, Diego Geroldi, Serena Bugatti, Roberto Caporali, Paola Rossi, Carlomaurizio Montecucco, Angela D'Angelo, Enzo Emanuele

Research output: Contribution to journalArticle

Abstract

Systemic lupus erythematosus (SLE) is characterized by an increased incidence of vascular disease which is only partially explained by traditional risk factors. Previous reports suggested that the level of lipoprotein(a) [Lp(a)], a particle linked to atherothrombotic disorders, is increased in patients with SLE. However, whether there are any differences in the distribution of apolipoprotein(a) [apo(a)] phenotypes between SLE patients and healthy controls remain to be determined. To address this issue, Lp(a) levels and apo(a) isoform size were analyzed in a total of 54 patients with SLE and in 108 age- and gender-matched healthy controls. SLE patients showed Lp(a) levels [median (interquartile range): 25.3 (6.5-51.0) vs. 9.5 (4.6-25.9) mg/dl, P=0.0109)] and a percentage of subjects with at least one small-sized apo(a) isoform (<or =25 K-IV repeats) significantly higher than controls (44.44% vs. 25.92%, P=0.0277). Multiple regression analysis adjusting for age, gender, disease duration, kidney involvement, the presence of active disease, as well as the carriage of at least one small apo(a) isoform revealed that only small apo(a) phenotypes were significant predictors of Lp(a) levels in SLE patients (P=0.0001). We conclude that genetic factors related to apo(a) size are a major determinant of elevated Lp(a) levels in patients with SLE. As small apo(a) phenotypes have been related to adverse vascular effects, it is feasible that small apo(a) isoforms may be a useful biological marker in the assessment of vascular risk in patients with SLE.

Original languageEnglish
Pages (from-to)661-665
Number of pages5
JournalInternational Journal of Molecular Medicine
Volume15
Issue number4
Publication statusPublished - Apr 2005

Fingerprint

Apoprotein(a)
Systemic Lupus Erythematosus
Lipoprotein(a)
Protein Isoforms
Phenotype
Blood Vessels
Kidney Diseases
Vascular Diseases
Biomarkers
Regression Analysis
Incidence

ASJC Scopus subject areas

  • Genetics

Cite this

Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. / Peros, Emmanouil; Geroldi, Diego; Bugatti, Serena; Caporali, Roberto; Rossi, Paola; Montecucco, Carlomaurizio; D'Angelo, Angela; Emanuele, Enzo.

In: International Journal of Molecular Medicine, Vol. 15, No. 4, 04.2005, p. 661-665.

Research output: Contribution to journalArticle

@article{91c54f8f5c7746ac8eff66d583bce63d,
title = "Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus.",
abstract = "Systemic lupus erythematosus (SLE) is characterized by an increased incidence of vascular disease which is only partially explained by traditional risk factors. Previous reports suggested that the level of lipoprotein(a) [Lp(a)], a particle linked to atherothrombotic disorders, is increased in patients with SLE. However, whether there are any differences in the distribution of apolipoprotein(a) [apo(a)] phenotypes between SLE patients and healthy controls remain to be determined. To address this issue, Lp(a) levels and apo(a) isoform size were analyzed in a total of 54 patients with SLE and in 108 age- and gender-matched healthy controls. SLE patients showed Lp(a) levels [median (interquartile range): 25.3 (6.5-51.0) vs. 9.5 (4.6-25.9) mg/dl, P=0.0109)] and a percentage of subjects with at least one small-sized apo(a) isoform (",
author = "Emmanouil Peros and Diego Geroldi and Serena Bugatti and Roberto Caporali and Paola Rossi and Carlomaurizio Montecucco and Angela D'Angelo and Enzo Emanuele",
year = "2005",
month = "4",
language = "English",
volume = "15",
pages = "661--665",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus.

AU - Peros, Emmanouil

AU - Geroldi, Diego

AU - Bugatti, Serena

AU - Caporali, Roberto

AU - Rossi, Paola

AU - Montecucco, Carlomaurizio

AU - D'Angelo, Angela

AU - Emanuele, Enzo

PY - 2005/4

Y1 - 2005/4

N2 - Systemic lupus erythematosus (SLE) is characterized by an increased incidence of vascular disease which is only partially explained by traditional risk factors. Previous reports suggested that the level of lipoprotein(a) [Lp(a)], a particle linked to atherothrombotic disorders, is increased in patients with SLE. However, whether there are any differences in the distribution of apolipoprotein(a) [apo(a)] phenotypes between SLE patients and healthy controls remain to be determined. To address this issue, Lp(a) levels and apo(a) isoform size were analyzed in a total of 54 patients with SLE and in 108 age- and gender-matched healthy controls. SLE patients showed Lp(a) levels [median (interquartile range): 25.3 (6.5-51.0) vs. 9.5 (4.6-25.9) mg/dl, P=0.0109)] and a percentage of subjects with at least one small-sized apo(a) isoform (

AB - Systemic lupus erythematosus (SLE) is characterized by an increased incidence of vascular disease which is only partially explained by traditional risk factors. Previous reports suggested that the level of lipoprotein(a) [Lp(a)], a particle linked to atherothrombotic disorders, is increased in patients with SLE. However, whether there are any differences in the distribution of apolipoprotein(a) [apo(a)] phenotypes between SLE patients and healthy controls remain to be determined. To address this issue, Lp(a) levels and apo(a) isoform size were analyzed in a total of 54 patients with SLE and in 108 age- and gender-matched healthy controls. SLE patients showed Lp(a) levels [median (interquartile range): 25.3 (6.5-51.0) vs. 9.5 (4.6-25.9) mg/dl, P=0.0109)] and a percentage of subjects with at least one small-sized apo(a) isoform (

UR - http://www.scopus.com/inward/record.url?scp=23044503429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044503429&partnerID=8YFLogxK

M3 - Article

C2 - 15754029

AN - SCOPUS:23044503429

VL - 15

SP - 661

EP - 665

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 4

ER -